Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability
The Journal of Sexual Medicine, 07/05/2012
Wang R et al. – Data suggest that avanafil may confer a safety benefit, in terms of a lower incidence of specific adverse events, by virtue of its high specificity to phosphodiesterase type 5 (PDE5) and its overall selectivity against other PDE isozymes.



